Company news

Share this article:
Boehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, a privately owned biotech company based in San Diego. The acquisition will occur through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis' leading asthma compound AP768. Upon successful completion of the entire development program, the total deal will be worth US$ 515 million. Further financial details were not disclosed. 
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.